CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Clinical trials for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) explained in plain language.
Never miss a new study
Get alerted when new CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) trials appear
Sign up with your email to follow new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for nerve disease: TAK-411 trial launches
Disease control Recruiting nowThis study tests a new medicine called TAK-411 for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a condition where the immune system attacks nerve coverings, causing weakness and numbness. The goal is to see if TAK-411 can improve physical function…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated May 26, 2026 08:24 UTC
-
CIDP patients switch to HyQvia: new study tracks Real-Life results
Disease control Recruiting nowThis study follows 30 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are switching to the treatment HyQvia. Researchers want to understand why patients chose this switch, how satisfied they are, and how the treatment affects their symptoms, daily…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Sponsor: Takeda • Aim: Disease control
Last updated May 26, 2026 08:24 UTC
-
New version of nerve disease drug tested for easier use
Disease control Recruiting nowThis study tests whether a new drug, TAK-881, works as well as an existing drug, HYQVIA, for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a nerve disorder causing weakness and numbness. About 59 participants who already receive immunoglobulin ther…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 19, 2026 12:01 UTC